Loading
A phase 1 trial of Relcobatinib run by Enliven Therapeutics, now recruiting.
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants is a phase 1 interventional study registered as NCT06787144 by Enliven Therapeutics, with 21 participants planned, started 2025-01-23. Conditions recorded: CML (Chronic Myelogenous Leukemia) and Chronic Phase CML. Interventions recorded: ELVN-001.
Shares Relcobatinib, Enliven Therapeutics, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Relcobatinib, Enliven Therapeutics, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/